NewAmsterdam Pharma Net Worth
NewAmsterdam Pharma Net Worth Breakdown | NAMSW |
NewAmsterdam Pharma Net Worth Analysis
NewAmsterdam Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including NewAmsterdam Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of NewAmsterdam Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform NewAmsterdam Pharma's net worth analysis. One common approach is to calculate NewAmsterdam Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares NewAmsterdam Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing NewAmsterdam Pharma's net worth. This approach calculates the present value of NewAmsterdam Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of NewAmsterdam Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate NewAmsterdam Pharma's net worth. This involves comparing NewAmsterdam Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into NewAmsterdam Pharma's net worth relative to its peers.
To determine if NewAmsterdam Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NewAmsterdam Pharma's net worth research are outlined below:
| NewAmsterdam Pharma is way too risky over 90 days horizon | |
| NewAmsterdam Pharma appears to be risky and price may revert if volatility continues | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.76 M. Net Loss for the year was (176.94 M) with profit before overhead, payroll, taxes, and interest of 33.59 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: NewAmsterdam Pharma Stock Price Down 4.9 percent - Should You Sell - MarketBeat |
Project NewAmsterdam Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.64) | (0.61) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.71) | (0.67) |
When accessing NewAmsterdam Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures NewAmsterdam Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NewAmsterdam Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in NewAmsterdam Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NewAmsterdam Pharma. Check NewAmsterdam Pharma's Beneish M Score to see the likelihood of NewAmsterdam Pharma's management manipulating its earnings.
Evaluate NewAmsterdam Pharma's management efficiency
The company has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4737) %, meaning that it generated substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2025. Return On Capital Employed is likely to climb to -0.61 in 2025. At this time, NewAmsterdam Pharma's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 6 M in 2025, whereas Total Assets are likely to drop slightly above 260.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.16 | 3.00 | |
| Tangible Book Value Per Share | 3.16 | 5.46 | |
| Enterprise Value Over EBITDA | (2.94) | (2.79) | |
| Price Book Value Ratio | 2.86 | 3.01 | |
| Enterprise Value Multiple | (2.94) | (2.79) | |
| Price Fair Value | 2.86 | 3.01 | |
| Enterprise Value | -208.5 M | -218.9 M |
Leadership at NewAmsterdam Pharma emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewAmsterdam Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smither John W over a month ago Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over two months ago Disposition of 430015 shares by Louise Kooij of NewAmsterdam Pharma at 10.0 subject to Rule 16b-3 | ||
Lewis William over three months ago Insider Trading | ||
Davidson Michael H. over six months ago Acquisition by Davidson Michael H. of 10399 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over six months ago Discretionary transaction by Louise Kooij of 213073 shares of NewAmsterdam Pharma subject to Rule 16b-3 |
NewAmsterdam Pharma Corporate Filings
F4 | 29th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of January 2025 Other Reports | ViewVerify | |
F3 | 17th of December 2024 An amendment to the original Schedule 13D filing | ViewVerify |
NewAmsterdam Pharma Earnings per Share Projection vs Actual
NewAmsterdam Pharma Corporate Management
| Louise Kooij | Treasurer, CFO | Profile | |
| Jim Jacobson | Chief Secretary | Profile | |
| Annie Neild | VP Affairs | Profile | |
| FESC MD | Chief Founder | Profile | |
| Marc MD | Chief Officer | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Lina Gugucheva | Chief Officer | Profile |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.